## **EXHIBIT C**



1

- 1 correct?
- 2 A. They are. They're called e-cigarettes, vape
- 3 products, or ENDS.
- 4 Q. Okay. And you talked a little bit about PMTAs
- 5 during your direct examination. And Reynolds has put in a
- 6 PMTA for its Solo product and its Vibe product, correct?
- 7 A. We have, yes.
- 8 Q. All right. It has also put in PMTAs for its
- 9 other e-cigarette devices, the Ciro and the Alto, correct?
- 10 A. Among other products, yes, that's correct.
- 11 Q. Okay. And you agree, Dr. Figlar, that if the
- 12 FDA denies Reynolds' PMTA applications for its Vuse
- 13 products, then Reynolds has to pull those products from the
- 14 market, correct?
- 15 A. If -- if that were the case, that would be true,
- 16 yes.
- 17 O. All right.
- 18 A. We don't feel that that's likely, but that would
- 19 be the case.
- 20 Q. I understand. But, Dr. Figlar, you don't know
- 21 if the FDA is going to authorize Reynolds' PMTAs for its
- 22 Vuse products, correct?
- 23 A. No, I don't know it but we're very, very
- 24 confident, obviously, in our applications. But, you know,
- 25 we don't -- we don't know until the FDA makes a judgment.

- 1 O. Right. So, Dr. Figlar, it's possible that the
- 2 Vibe and the Solo domestic industry products will have to
- 3 be removed from the market this year, right?
- 4 A. This year, I'm not sure. It depends on when the
- 5  $\,$  FDA is going to make a decision before one would have to,
- 6 you know, remove products from the market. But, you know,
- 7 we will see.
- 8 O. Well, if the FDA denies the applications,
- 9 Reynolds is going to pull the products, correct?
- 10 A. Well, obviously I think Reynolds would -- would
- 11 run the course of -- of administrative review, but -- but,
- 12 yes, if ultimately the FDA makes that decision, then we
- 13 would have to remove those products from the market.
- Q. Okay. Now, there's another FDA term that's been
- 15 discussed in this case called an MRTPA, correct?
- 16 A. I suppose, yes, I know what an MRTPA is, yes.
- 17 O. Right. An MRTPA stands for Modified Risk
- 18 Tobacco Product Application, correct?
- 19 A. That is correct.
- 20 Q. Right. And if an MRT application is granted, a
- 21 company can advertise a tobacco product as, for instance, a
- 22 reduced risk or a reduced exposure product, correct?
- 23 A. It depends on what the FDA decides with regard
- 24 to those advertising claims, but, yes, there's a G-1 and
- 25 G-2 path, exposure or risk.

